tbuckley/cabot-search huggingface dataset:
Management of Acne Vulgaris
Authors: Carly J. Roman, Adam S. Cifu, Sarah L. Stein
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prediabetes Risk in Adult Americans According to a Risk Test
Authors: Saeid Shahraz, Anastassios G. Pittas, David M. Kent
Journal: JAMA Internal Medicine (2016)

Using data from the 2013-2014 NHANES population, this study provides an estimate of the proportion of nondiabetic adults who would be classified as being at high risk for prediabetes according to a web-based risk test.
Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab.
Authors: Evdoxia Hatjiharissi, Daniel Ditzel Santos, Lian Xu, Sigitas Verselis, Michael Modica, Xavier Leleu, Zachary Hunter, Allen W. Ho, Robert Manning, Christopher Patterson, Kenneth C. Anderson, Edward Fox, Steven P. Treon
Journal: Blood (2005)
Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis
Authors: Philipp Dahm, Michelle Brasure, Roderick MacDonald, Carin M. Olson, Victoria A. Nelson, Howard A. Fink, Bruce Rwabasonga, Michael C. Risk, Timothy J. Wilt
Journal: European Urology (2016)
The Patient I Thought I Knew
Authors: Darlene Yvette Robinson
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma
Authors: Pedram Gerami, Zuxu Yao, David Polsky, Burkhard Jansen, Klaus Busam, Jonhan Ho, Mary Martini, Laura K. Ferris
Journal: Journal of the American Academy of Dermatology (2016)

Clinical and histopathologic assessment of pigmented skin lesions remains challenging even for experts. Differentiated and accurate noninvasive diagnostic modalities are highly desirable.We sought to provide clinicians with such a tool.A 2-gene classification method based on LINC00518 and preferentially expressed antigen in melanoma (PRAME) gene expression was evaluated and validated in 555 pigmented lesions (157 training and 398 validation samples) obtained noninvasively via adhesive patch biopsy. Results were compared with standard histopathologic assessment in lesions with a consensus diagnosis among 3 experienced dermatopathologists.In 398 validation samples (87 melanomas and 311 nonmelanomas), LINC00518 and/or PRAME detection appropriately differentiated melanoma from nonmelanoma samples with a sensitivity of 91% and a specificity of 69%. We established LINC00518 and PRAME in both adhesive patch melanoma samples and underlying formalin fixed paraffin embedded (FFPE) samples of surgically excised primary melanomas and in melanoma lymph node metastases.This technology cannot be used on mucous membranes, palms of hands, and soles of feet.This noninvasive 2-gene pigmented lesion assay classifies pigmented lesions into melanoma and nonmelanoma groups and may serve as a tool to help with diagnostic challenges that may be inherently linked to the visual image and pattern recognition approach.
Highlighting the challenge of delayed overall survival (OS) curve separation in immunotherapy clinical trials.
Authors: Savanna D. Steele, Song Wang, Alan Solinger, Austin J. Combest, Marie-Edith Anne Bonneterre, Dirk J. Reitsma
Journal: Journal of Clinical Oncology (2013)

3009 Background: Cancer immunotherapy holds great potential but can elicit delayed responses, unlike chemotherapy. A delay in the separation of OS curves (between the control and treatment arms) has led to difficulty in achieving adequate power for OS analysis (Hoos A, Ann Oncol. 2012). Since combining immunotherapies, such as an anti-CTLA4 and an anti-PD-1, may increase the percentage of subjects achieving durable responses (Curran MA, PNAS. 2010), we sought to determine how adding a complementary immunologic agent to the currently-approved ipilimumab would impact delay in OS curve separation. Arbitrarily assuming that treatment effect on OS was doubled, we determined how various delays in OS curve separation might impact sample sizes. Methods: We evaluated three dual-immunotherapy clinical trial scenarios in which the separation of OS curves either remained the same, decreased, or increased. Baseline OS estimates were from pivotal trial data for ipilimumab in melanoma (Robert C et al, NEJM. 2011). SAS PROC POWER with piecewise linear survival curve was then used to determine approximate corresponding sample sizes. Results: See Table. Conclusions: Demonstrating significance in order to gain regulatory approval is important for providing potentially life-saving medications. For trials evaluating dual-immunotherapies, despite doubling treatment effects, delays in OS curve separation of up to 6 months would require over 2700 subjects to reach statistical power. In an era where treatments are increasingly personalized, these numbers will be difficult to achieve, underscoring the importance of novel trial designs incorporating Bayesian hierarchical modeling, precompetitive collaborations, and/or the use of state-of-the-art predictive biomarkers. [Table: see text]
Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment
Authors: Donald R. Sullivan, Christopher W. Forsberg, Linda Ganzini, David H. Au, Michael K. Gould, Dawn Provenzale, Christopher G. Slatore
Journal: Journal of Clinical Oncology (2016)

Purpose Depression symptoms are common among patients with lung cancer; however, longitudinal changes and their impact on survival are understudied. Methods This was a prospective, observational study from the Cancer Care Outcomes Research and Surveillance Consortium from five US geographically defined regions from September 2003 through December 2005. Patients enrolled within 3 months of their lung cancer diagnosis were eligible. The eight-item Center for Epidemiologic Studies Depression scale was administered at diagnosis and 12 months’ follow-up. The main outcome was survival, which was evaluated using Kaplan-Meyer curves and adjusted Cox proportional hazards modeling. Results Among 1,790 participants, 681 (38%) had depression symptoms at baseline and an additional 105 (14%) developed new-onset depression symptoms during treatment. At baseline, depression symptoms were associated with increased mortality (hazard ratio [HR], 1.17; 95% CI, 1.03 to 1.32; P = .01). Participants were classified into the following four groups based on longitudinal changes in depression symptoms from baseline to follow-up: never depression symptoms (n = 640), new-onset depression symptoms (n = 105), depression symptom remission (n = 156), and persistent depression symptoms (n = 254) and HRs were calculated. Using the never-depression symptoms group as a reference group, HRs were as follows: new-onset depression symptoms, 1.50 (95% CI, 1.12 to 2.01; P = .006); depression symptom remission, 1.02 (95% CI, 0.79 to 1.31; P = .89), and persistent depression symptoms, 1.42 (95% CI, 1.15 to 1.75; P = .001). At baseline, depression symptoms were associated with increased mortality among participants with early-stage disease (stages I and II; HR, 1.61; 95% CI, 1.26 to 2.04), but not late-stage disease (stages III and IV; HR, 1.05; 95% CI, 0.91 to 1.22). At follow-up, depression symptoms were associated with increased mortality among participants with early-stage disease (HR, 1.71; 95% CI, 1.27 to 2.31) and those with late-stage disease (HR, 1.32; 95% CI, 1.04 to 1.69). Conclusion Among patients with lung cancer, longitudinal changes in depression symptoms are associated with differences in mortality, particularly among patients with early-stage disease. Symptom remission is associated with a similar mortality rate as never having had depression.
Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Adriana C Rossi, Ekta Aneja, Angelique Boyer, David Jayabalan, Tomer M Mark, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, Ruben Niesvizky
Journal: Blood (2014)
Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer
Authors: Huan Qiao, Christine M. Lovly
Journal: Cancer Discovery (2016)

Abstract Summary: In the setting of recent exciting clinical results and numerous ongoing trials, Gainor and colleagues explored mechanisms of acquired resistance to first- and second-generation ALK inhibitors in ALK-rearranged non–small cell lung cancer and found that an increased frequency and distinct spectrums of resistance mutations emerged with the more potent second-generation inhibitors. Their findings have important and immediate clinical implications as the resistance mutations detected impart differential sensitivities to available ALK inhibitors, thereby highlighting the need for sequential biopsies with molecular testing to determine the most effective treatment strategy upon disease progression. Cancer Discov; 6(10); 1084–6. ©2016 AACR. See related article by Gainor et al., p. 1118.
Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.
Authors: G. A. McArthur, I. Puzanov, A. Ribas, P. B. Chapman, K. B. Kim, J. A. Sosman, R. J. Lee, K. B. Nolop, K. T. Flaherty, R. Hicks
Journal: Journal of Clinical Oncology (2010)

8529 Background: FDG-PET is an effective imaging modality at assessing early response to a variety of agents that target key driver mutations in human cancer. Reduction in FDG uptake reflects inhibition of glycolytic metabolism and presumably rapid cell death and thus may provide early information on patient benefit. We aimed to determine the response rate using FDG-PET in patents with advanced melanoma treated with PLX4032 as defined by EORTC FDG-PET response criteria in target lesions in an international multicenter phase I study. Methods: Baseline and day 15 FDG PET were available in 22 pts with advanced metastatic melanoma treated at 3320mg BID. The cohort included 19 pts treated at 960mg BID, the MTD of PLX4032. As controls we analyzed 4 pts with advanced melanoma treated on the same study but at subtherapeutic doses (AUC uM*h 0-24 of 69±8, <10% of pts dosed at the MTD). Results: Strikingly all 22 pts treated at 3320mg BID had at least a partial metabolic response (PMR->25% reduction in SUVMax), with 3 achieving complete metabolic response (CMR). In the 19 pts with PMR there was a 84±3% reduction in target lesion SUVmax, 90±4% decrease in the % of injected dose (%ID) in all identified disease sites and a decrement in metabolic volume by 79±5%. In contrast no metabolic responses were seen in the 4 control subjects. The overall RECIST response rate in the cohort of 22 pts was 86%, with 17 PRs and 2 CRs. There appeared to be no relation between either SUVmax or metabolic tumor burden at baseline, and extent of PET response, with one of the pts achieving CMR having over 3kg of disease at baseline. There was a positive correlation between %ID in all identified disease and %ID in target lesions (r2 0.52, p=0.002) indicating significant homogeneity of response between lesions in individual pts. No relationship was found between reduction in target lesion SUVmax and response by RECIST, progression free survival, or time to achieve RECIST PR. Conclusions: FDG-PET is a useful marker of early biologic response in BRAF mutant melanoma treated with PLX4032. Little heterogeneity in PET response was found between lesions in individual pts suggesting minimal intrapatient molecular heterogeneity with respect to effects of BRAF inhibition in pts with metastatic melanoma. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Plexxikon, Roche Roche Plexxikon Roche Plexxikon, Roche
Abstract 214: Role Of Sirtuin 6 In Macrophage Polarization In Diabetes
Authors: G V Velmurugan, Suresh K Verma, Alexander R Mackie, Erin E Vaughan, Raj kishore, Prasanna Krishnamurthy
Journal: Circulation Research (2013)

Clinical and experimental studies provide evidence that metabolic and inflammatory pathways are functionally interconnected to cardiovascular diseases. Dynamic changes in macrophage activation [classical M1 activation (promote inflammation) or alternative M2 activation (promote wound healing)], in response to various signals, modulate tissue pathology in diabetes. Sirtuin 6 (SIRT6), a NAD-dependent nuclear deacetylase plays an important role in genomic stability, cellular metabolism, stress response and aging. However, the mechanism by which SIRT6 activity affects macrophage function in diabetes is still unclear. Mouse bone marrow-derived macrophages (BMM) exposed to high glucose (HG, 25mM D-glucose) showed reduced expression of SIRT6 as compared to low glucose (LG, 5mM D-glucose)- and osmotic control (OC, 5mM D-glucose+20mM D-mannitol)-treated cells. SIRT6 knockdown in RAW 264.7 cells exaggerated inflammatory response in macrophages exposed to high glucose (HG) and in contrast, IL4-induced alternative macrophage (M2) phenotype was defective in SIRT6 deficient BM-macrophages under high glucose condition. SIRT6 protein expression was low in failing (MI-induced) and diabetes-affected hearts. Interestingly, mice receiving intramyocardial injection of SIRT6-deficient macrophages showed further deterioration in LV function, post-MI. Taken together, these data highlighting a role for SIRT6 in regulating both M1 and M2 polarization might have broad implications for numerous inflammatory disease states including insulin resistance and wound healing.
NFATC3 promotes IRF7 transcriptional activity in plasmacy­­toid dendritic cells
Authors: Musheng Bao, York Wang, Ying Liu, Peiqing Shi, Hongbo Lu, Wenwen Sha, Leiyun Weng, Shino Hanabuchi, Jun Qin, Joel Plumas, Laurence Chaperot, Zhiqiang Zhang, Yong-Jun Liu
Journal: The Journal of Experimental Medicine (2016)

Plasmacytoid dendritic cells (pDCs) rapidly produce large amounts of type 1 interferon (IFN) after Toll-like receptor 7 and 9 engagements. This specialized function of type 1 IFN production is directly linked to the constitutive expression of IRF7, the master transcription factor for type 1 IFN production. However, the IRF7 regulatory network in pDCs remains largely unknown. In this study, we identify that the transcription factor NFATC3 specifically binds to IRF7 and enhances IRF7-mediated IFN production. Furthermore, knockout of NFATC3 greatly reduced the CpG DNA-induced nuclear translocation of IRF7, which resulted in impaired type 1 IFN production in vitro and in vivo. In addition, we found that NFATC3 and IRF7 both bound to type 1 IFN promoters and that the NFAT binding site in IFN promoters was required for IRF7-mediated IFN expression. Collectively, our study shows that the transcription factor NFATC3 binds to IRF7 and functions synergistically to enhance IRF7-mediated IFN expression in pDCs.
Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies
Authors: Ruth C. Travis, Angela Balkwill, Georgina K. Fensom, Paul N. Appleby, Gillian K. Reeves, Xiao-Si Wang, Andrew W. Roddam, Toral Gathani, Richard Peto, Jane Green, Timothy J. Key, Valerie Beral
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: It has been proposed that night shift work could increase breast cancer incidence. A 2007 World Health Organization review concluded, mainly from animal evidence, that shift work involving circadian disruption is probably carcinogenic to humans. We therefore aimed to generate prospective epidemiological evidence on night shift work and breast cancer incidence. Methods: Overall, 522 246 Million Women Study, 22 559 EPIC-Oxford, and 251 045 UK Biobank participants answered questions on shift work and were followed for incident cancer. Cox regression yielded multivariable-adjusted breast cancer incidence rate ratios (RRs) and 95% confidence intervals (CIs) for night shift work vs no night shift work, and likelihood ratio tests for interaction were used to assess heterogeneity. Our meta-analyses combined these and relative risks from the seven previously published prospective studies (1.4 million women in total), using inverse-variance weighted averages of the study-specific log RRs. Results: In the Million Women Study, EPIC-Oxford, and UK Biobank, respectively, 673, 28, and 67 women who reported night shift work developed breast cancer, and the RRs for any vs no night shift work were 1.00 (95% CI = 0.92 to 1.08), 1.07 (95% CI = 0.71 to 1.62), and 0.78 (95% CI = 0.61 to 1.00). In the Million Women Study, the RR for 20 or more years of night shift work was 1.00 (95% CI = 0.81 to 1.23), with no statistically significant heterogeneity by sleep patterns or breast cancer risk factors. Our meta-analysis of all 10 prospective studies included 4660 breast cancers in women reporting night shift work; compared with other women, the combined relative risks were 0.99 (95% CI = 0.95 to 1.03) for any night shift work, 1.01 (95% CI = 0.93 to 1.10) for 20 or more years of night shift work, and 1.00 (95% CI = 0.87 to 1.14) for 30 or more years. Conclusions: The totality of the prospective evidence shows that night shift work, including long-term shift work, has little or no effect on breast cancer incidence.
Patient-centered conversations: Advance care planning values in the adult oncology population.
Authors: Sabrina Q. Mikan, J. Russell Hoverman
Journal: Journal of Clinical Oncology (2014)

147 Background: Over the past 2 years a structured advance care planning program (ACP) has been created, piloted and is evaluated monthly at 10 Texas Oncology practices. This program is a systematic process for assessing patient values, is physician supported and is delivered by advanced practice providers at each site. Patient values and quality of life are at the center of the conversations, enhancing patient-centered care and communication with their oncology providers. Targeted patient populations include metastatic lung, pancreatic and colon cancers. Methods: Over the past 14 months, 332 patients engaged in ACP in ten sites. Descriptive statistics for each site were calculated and examined to explore 1) ACP counseling sessions, 2) number of Patient Values questionnaires completed, 3) frequency of code status documentation in the health record, and 4) hospice enrollment for both the targeted and all metastatic populations. Results: A three month review revealed the ACP work within all metastatic populations at the ten sites. Targeted population totals showed continued increase in the percentages of patient ACP engagement at each site. For the practice as a whole, and the targeted population, 9-23% of patients have received an ACP counseling visit. There have been 149 completed Patient Values questionnaires. In the electronic health record, there are 2,233 (24%) patients who have a documented code status. A range of hospice enrollment from 8-28% in the targeted populations has continued to improve hospice length of stay. Conclusions: The patient is invited to explore their treatment options, their personal values and the completion of the advance directive documents. Truthful conversations are critical between patient and provider in order to create a meaningful treatment plan, and to allow the patient to gain understanding about their options. Early palliative care referrals are integrated into each session for symptom management through local partnerships with palliative care physicians. Education regarding life-sustaining interventions help the patient determine their choices for medical care. Having ACP counseling is important at any stage of health and particularly within life-limiting disease.